Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

NCT04356729 is registered in ClinicalTrials.gov with F. Stephen Hodi, MD as lead sponsor.

NCT NCT04356729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04356729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Lead sponsor
F. Stephen Hodi, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 6, 2020
Completion date
June 1, 2028
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii cutaneous melanoma ajcc v8, stage iv melanoma, unresectable stage iii cutaneous melanoma, unresectable stage iv cutaneous melanoma